We have previously shown that Regulator of Calcineurin 1 (RCAN1) regulates multiple stages of vesicle exocytosis. However, the mechanisms by which RCAN1 affects secretory vesicle exocytosis and quantal release kinetics remain unknown. Here we use carbon fiber amperometry to detect exocytosis from chromaffin cells and identify these underlying mechanisms. We observe reduced exocytosis with repeated stimulations in chromaffin cells overexpressing RCAN1 (RCAN1 
Introduction
Regulator of Calcineurin 1 (RCAN1) is a chromosome 21 gene that is over expressed in Down syndrome (DS) and Alzheimer's disease (AD) brains (Ermak et al. 2001 , Fuentes et al. 2000 . Human DS and AD brains demonstrate neuronal changes including reduced noradrenaline signalling, basal forebrain cholinergic neuron degeneration, enlarged endosomes and dementia (Lai et al. 1999) . Mouse models of both disorders demonstrate reduced synaptic transmission, LTP and altered learning and memory (Oddo et al. 2003 , Siarey et al. 2005 . Identifying proteins common to both DS and AD which have roles in cell signalling or neurotransmitter release may enhance our understanding of the mechanisms underlying the neuronal changes observed in these disorders.
We have previously identified RCAN1 as a novel regulator of vesicle release and quantal release kinetics . These experiments were undertaken in mouse adrenal chromaffin cells using carbon fibre amperometry, a method which measures the number of individual vesicles undergoing exocytosis and the amount released from each vesicle. Additionally, exocytotic events in these cells are often associated with a pre-spike "foot" (PSF) signal that represents release of catecholamine during the formation of a stable fusion pore. We previously illustrated that altering RCAN1 expression reduces the number of exocytotic events occurring in chromaffin cells . We also observe that increased levels of RCAN1 reduced the amount released from individual vesicles and decreased PSF signal duration ). These effects do not appear to be due to changes in vesicle loading or size, alterations in Ca 2+ entry or the size of the readily releasable pool of vesicles.
The most well characterised role of RCAN1 is as an inhibitor of calcineurin activity (Fuentes et al. 2000 , Rothermel et al. 2000 . There are several potential mechanisms by which RCAN1 might regulate exocytosis and quantal release kinetics via its effects on calcineurin activity. Reduced calcineurin activity caused by RCAN1 overexpression could alter the phosphorylation and activity of a number of calcineurin targets involved in exocytosis and vesicle recycling such as Munc18 , dynamin 1, amphiphysin 1/2 and synaptojanin (Cousin & Robinson 2001) . Such an explanation focuses on the effect that relatively acute alterations in calcineurin activity could have on these processes. Chronic alterations in calcineurin activity may also have transcriptional effects via the well-characterised calcineurin/NFAT signalling node, which regulates presynaptic neurotransmitter release (Freeman et al. 2011) . RCAN1 may also affect exocytosis and quantal release kinetics via direct mechanisms that are independent of its effect on calcineurin activity.
Here we identify the role of calcineurin activity associated with the regulation of exocytosis by RCAN1. Increased RCAN1 expression reduces vesicle endocytosis and recycling in a repeated stimulation protocol and this effect is caused by the inhibition of calcineurin in cell overexpressing RCAN1. Chronic (3 days in vitro) calcineurin inhibition in WT cells replicates the changes in quantal release kinetics observed in RCAN1 ox cells and such calcineurin inhibition has no additional effect of the amount of catecholamine released per vesicle in RCAN1 ox cells. This treatment in RCAN1 ox cells does, however, have further effect on PSF signal kinetics illustrating an effect of RCAN1 on early quantal release stability that is independent of its effects on calcineurin activity. Electron microscopy confirms that RCAN1 overexpression does not affect vesicle distribution or morphology in chromaffin cells. Therefore, increased RCAN1 expression inhibits calcienrin activity to negatively effect the amount of vesicle content released as well as affects vesicle endocytosis and recycling.
Materials and Methods
Chromaffin cell culture Adrenal glands were taken from 6-8 week-old male wild type (WT) and RCAN1 ox mice and chromaffin cells were prepared as previously as approved by the Flinders University Animal Welfare Committee. Briefly, the adrenal medulla was dissected out in cold Locke's buffer (154 mM NaCl, 5.6 mM KCl, 3.6 mM NaHCO 3 , 5.6 mM glucose, 5.0 mM HEPES, pH 7.4) and then incubated with collagenase type A (Roche, Germany) in Locke's buffer at a concentration of 3 mg/ml in a shaking bath at 37 o C. The collagenase was diluted further in cold Locke's buffer, cells pelleted and resuspended in cell culture medium (DMEM medium supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin (Invitrogen, Carlsbad, CA, USA), 2mM L-glutamine (Invitrogen, Carlsbad, CA, USA) and 10% FCS (JRH Biosciences, Lenexa, USA)) and filtered through nylon mesh. Cells were pelleted, resuspended in supplemented DMEM and plated on 35 mm culture dishes and incubated at 37 o C with 5% CO 2 . Cells were maintained in primary culture for 3 to 4 days prior to experiments.
Carbon Fiber Amperometry
Catecholamine release from single chromaffin cells was measured using amperometry (Maritzen et al. 2008 , Yu et al. 2008 . A carbon fibre electrode (ProCFE, Dagan Corporation, USA) was placed on a chromaffin cell and +800 mV applied to the electrode under voltage clamp conditions. Current due to catecholamine oxidation was recorded using an EPC-9 amplifier and Pulse software (HEKA Electronic, Germany), sampled at 10 kHz and low-pass filtered at 1 kHz. For quantitative analysis, files were converted to Axon Binary Files (ABF Utility, version 2.1, Synaptosoft, USA) and secretory spikes analysed (Mini Analysis, version 6.0.1, Synaptosoft, USA) for a period of 60s from the start of stimulation. The standard bath solution (Krebs buffer) contained 140 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 1mM MgCl 2 , 5mM D-glucose, 10 mM HEPES, pH 7.4. High K + -containing solution was the same as the control bath solution except that 70 mM K + replaced an equimolar amount of NaCl. All solutions were applied to cells using a gravity perfusion system, the outlet of which was placed within 500µm from the recorded cell. All experiments were carried out at room temperature (22-24 o C). Acute and chronic calcineurin inhibition experiments were conducted using solutions containing FK-506 (5μM) and cyclosporine A (5μM) (Sigma Australia). Acute treatments involved incubating cells with inhibitors in Krebs buffer for 5 minutes at room temperature prior to stimulations, which were then carried out in the presence of the inhibitors. Chronic inhibition treatment involved incubating chromaffin cells, prepared the previous day, in cell culture medium containing the inhibitors for 3 days at 37 o C with 5% CO 2 . Stimulations were performed using Krebs buffers containing the inhibitors.
Amperometry data analysis
Data analysis was performed as previously described . Briefly, amperometric spikes were selected for analysis of event frequency if spike amplitude exceeded 10 pA and overlapping peaks were included. For kinetic analysis of spikes and PSF signals, only those events which exceeded 20 pA or were not overlapping with other spikes were included. Only pre-spike foot features longer than 1 ms and >2.5 times the RMS noise of the baseline in that recording were analyzed as foot signals.
Electron microscopy
Adrenal tissue was fixed and stained using a modified chromaffin reaction (Tranzer & Richards 1976) . Adrenal glands were fixed for 6 hours at 4C in 0.1M phosphate buffer (PB) pH 7.2, containing 3% glutaraldehyde. The tissue was then transferred to 0.1M PB, pH 7.2 and kept overnight at 4C. The samples were washed 3 times in 0.1M PB before being post-fixed in 1% osmium tetroxide in 0.1M PB, pH 7.2 for 1hr at room temperature. After multiple washes the tissue was stained with 2% aqueous uranyl acetate for 30 minutes. Following a series of dehydration steps with ethanol solutions (50%-100%) and propylene oxide, the tissue was incubated for 1 hour in a 1:1 mixture of propylene oxide: Durcupan resin (Sigma; Sigma-Aldrich Pty Ltd, Castle Hill, Australia). The samples were then embedded in pure resin in capsules and polymerization was carried out for 48 hours at 60C. An ultramicrotome (RMC Mechanical Advance Ultramicrotome) was used to cut thick sections (1µm) which were stained with 1% toluidine blue in 1% borax for light microscopic examinations. Ultrathin sections (80-100nm) were cut using a diamond knife (Diatome) and sections were mounted on single-slot copper grids which were coated with 0.6% -0.8% Butvar solution in chloroform. The sections were then stained with Reynolds' lead citrate solution (Reynolds 1963 ) and allowed to dry overnight. The ultra-thin sections were observed under transmission electron microscopy (JOEL1200-EX transmission electron microscope), and images were taken at 30,000 magnification. Ultrastructural images were captured with a Megaview3 camera using the ITEM interface program. Higher resolution montages of selected cells were compiled using the Multiple Image Alignment module in ITEM.
Chromaffin granule counting and statistics
Images were analyzed using ImageJ software (NIH). The number and spatial distribution of LDCVs were evaluated on micrographs covering the entire cell's cytoplasmic region. LDCVs were identified by their electron-dense core and circular membrane. To measure vesicle localisation, 200 nm-wide concentric zones starting from the cell membrane were defined within each cell and the number of dense core vesicles within each region counted and presented as a percentage of the total number of vesicles. Dense core and vesicle diameter were measured from 50 vesicles per cell. Representative regions within the cell were selected by overlaying a numbered grid on each electron micrograph. A random number generator was then used to identify the LDCV containing regions to be analysed. All electron micrographs taken at a magnification of 4000X and were analyzed using ImageJ image analysis software (NIH).
Statistical analysis
For amperometry whole spike analysis, as data is not parametrically distributed we obtain the median value in each recording and present the final data as the mean of these median values (Maritzen et al. 2008) . This data is then analysed using a Student's unpaired t-test. For PSF analysis we often do not obtain sufficient data points to use the median value from each recording. Therefore for these parameters we obtain the mean of each individual value and gauge statistical differences between the means of different groups using the Mann-Whitney test. All data are presented as mean ± SEM. For electron microscopy analysis, data is represented as the average number of LDCVs per unit area ± SEM. Data for each genotype was compared using a Student's unpaired t-test. In all statistical tests significance was obtained at p<0.05.
Results

RCAN1 overexpression does not alter vesicle localisation in chromaffin cells
We have previously demonstrated changes in exocytosis in RCAN1 ox chromaffin cells . We therefore used electron microscopy to analyse whether changes in exocytosis in RCAN1 ox cells may be due to alterations in vesicle number and localisation. The ultrastructural appearance of WT ( Figure 1A ) and RCAN1 ox ( Figure 1B ) chromaffin cells appears similar and we find that the average number of vesicles per unit area is not different between WT (n=7 cells) and RCAN1 ox cells (n=9 cells, Figure 1C ). We also assessed the distribution of vesicles with regard to their distance from the plasma membrane in these cells. We find no differences in the average distance from the membrane between WT and RCAN1 ox cells ( Figure 1D ). These results indicate that altered exocytosis in RCAN1 ox chromaffin cells is not due to altered vesicle number or distribution. We additionally measured vesicle size in these cells and observe a significant decrease both in mean vesicle diameter ( Figure 1E , p<0.001) and dense core diameter ( Figure 1F, p<0.001 ). This data indicates that catecholamine loading into vesicles is negatively affected in RCAN1 ox chromaffin cells.
RCAN1 regulates vesicle recycling in chromaffin cells by inhibiting calcineurin.
Calcineurin controls endocytosis primarily through regulation of the activity of the endocytic proteins known as the dephosphins (Cousin & Robinson 2001) . As endocytosis and exocytosis are directly interlinked, we wished to know whether endocytosis and vesicle recycling defects might underlie reduced levels of exocytosis in RCAN1 ox cells. To gauge this we implemented a repeated stimulations protocol, consisting of three one-minute stimulations with 5 minute intervals between them that reflects the release of vesicles that have been endocytosed in a dynamin-dependent manner after the initial stimulation (Elhamdani et al. 2001) . This protocol induces consistent levels of exocytosis in WT cells (Figure 2A-D) . However when we acutely inhibit calcineurin activity in WT cells using the calcineurin inhibitors cyclosporine A and FK-506, the result is a decline (P<0.05) in the number of vesicles undergoing exocytosis during subsequent stimulations ( Figure 2E-H) . This indicates that calcineurin controls vesicle recycling in WT chromaffin cells and that acute exposure to known inhibitors of calcineurin activity causes a rundown of secretion with this repeated stimulation protocol. We repeated these experiments in RCAN1 ox chromaffin cells. RCAN1 ox cells display a rundown in exocytosis in the absence of any calcineurin inhibitors using this protocol ( Figure 3A-D) , indicative of a recycling defect in RCAN1 ox chromaffin cells. Importantly, acute exposure to inhibitors of calcineurin in RCAN1 ox cells has no additional effect on vesicle recycling compared to RCAN1 ox cells in the absence of these inhibitors ( Figure 3E-H) . These results therefore support the possibility that calcineurin activity controls vesicle recycling in chromaffin cells and that RCAN1 overexpression in RCAN1 ox cells may inhibit vesicle recycling due to reduced activity of calcineurin.
Repeated acute inhibition of calcineurin does not alter quantal release kinetics.
Our previous studies identified a role for RCAN1 in the regulation of the amount of catecholamine released from individual vesicles and that this change was not replicated when we acutely inhibited calcineurin and stimulated cells a single time . However, we find in the present study that vesicle recycling is reduced following repeated stimulations in the presence of calcineurin inhibitors. We hypothesise that this is due to altered dephosphorylation of calcineurin target proteins involved in vesicle fission and fusion. As the phosphorylation status of some exocytosis proteins, such as Munc-18 , is affected by calcineurin activity, we therefore wished to identify if quantal release kinetics are also affected during this repeated stimulations protocol in the presence of cyclosporine A and FK-506. We therefore analysed the spike kinetics from the previous experiments in which we acutely exposed cells to cyclosporine A and FK-506 for 10 minutes in WT cells and repeatedly stimulated cells in the continued presence of these drugs. We find that this has no effect on vesicle release kinetics such as amperometric spike area ( Figure 4A ), rise time ( Figure 4B ), half-width ( Figure 4C ) or decay time ( Figure  4D ). Therefore, short-term exposure to calcineurin inhibitors, even during repeated stimulations, does not affect quantal release kinetics and the amount of catecholamine released per vesicle.
RCAN1 overexpression may reduce the amount released per vesicle via the chronic inhibition of calcineurin activity.
As calcineurin activity is thought to be chronically, rather than acutely, inhibited in RCAN1 ox cells, we next investigated whether chronic exposure to calcineurin inhibitors could explain the effect of RCAN1 overexpression on vesicle release in RCAN1 ox chromaffin cells. We cultured chromaffin cells for 3 days in the presence or absence of cyclosporine A and FK-506 and compared the effect on amperometric spike kinetics in both WT and RCAN1 ox cells. Chronic exposure to calcineurin inhibitors reduced the total amount of catecholamine released per vesicle in WT cells ( Figure 5A ). Unsurprisingly therefore, the rise time ( Figure 5B ), half-width ( Figure  5C ) and decay time ( Figure 5D ) of WT spikes were also changed during chronic exposure to cyclosporine A and FK-506. When we undertook these experiments in RCAN1 ox cells we observe the reduced release from vesicles that we previously published . Importantly, when we chronically exposed RCAN1 ox cells to cyclosporine A and FK-506 we observe no additional decrease in these spike parameters. Thus it is possible that chronic inhibition of calcineurin activity reduces quantal release kinetics and that the reduced amount of catecholamine released from RCAN1 ox vesicles may be due to chronic inhibition of calcineurin caused by RCAN1 overexpression.
Calcineurin activity may also be important for regulating release during the earliest stages of exocytosis.
In amperometric recordings, a pre-spike foot (PSF) signal is often observed before a full secretory spike. This PSF represents the release of catecholamine through the developing fusion pore as it transitions to a stable, fully dilated pore. As we previously reported reductions in the PSF signal when RCAN1 is overexpressed, we analysed changes in the PSF signal in WT and RCAN1 ox cells when cells are chronically exposed to cyclosporine A and FK-506. In WT cells we observe no change in PSF signal amplitude when cells are exposed to these drugs ( Figure 6A ) but do observe significant decreases in PSF signal duration (P<0.001, Figure 6B ) and area (P<0.001, Figure 6C ). In RCAN1 ox cells, chronic calcineurin inhibition caused a significant decrease in PSF signal duration (P<0.001) and area (P<0.01).
Discussion
We have previously shown that RCAN1 is a regulator of exocytosis and is involved in the regulation of both the amount of catecholamine released from vesicles and the number of vesicles undergoing fusion . In the present study we reveal further insights into the role of RCAN1 in the regulation of exocytosis. We firstly identify that overexpression of RCAN1 and the acute use of pharmacological agents which inhibit calcineurin activity both reduce vesicle recycling and re-use. Furthermore the combination of these two treatments has no additive effect in our vesicle recycling assay. These effects are not caused by changes in vesicle number or distribution as evidenced from our electron microscopy studies. Short term (minutes) use of drugs known to inhibit calcineurin activity does not affect the amount of catecholamine released per vesicle during our repeated stimulation protocol. However when we chronically (days) expose cells to these calcineurin inhibitors, as would occur if RCAN1 overexpression were inhibiting calcineurin in RCAN1 ox cells, we find the amount of catecholamine released from single vesicles to be drastically reduced to a simlar level to that seen in RCAN1 ox cells. Our finding that the chronic use of calcineurin inhibitors does not have any additional effect on vesicle release in RCAN1 ox cells suggests that RCAN1 overexpression in these cells reduces quantal vesicle release via the inhibition of calcineurin activity. Our EM analysis further illustrates that the underlying mechanism explaining reduced vesicle release in RCAN1 ox cells is a reduced catecholamine loading into vesicles. Intriguingly however, we still observe an effect of cyclosporine A and FK-506 in RCAN1 ox cells on the PSF signal.
The progressive decrease in exocytosis observed with our repeated stimulation protocol in the presence of cyclosporine A and FK506 suggests that vesicle endocytosis and recycling are impaired when calcineurin activity is blocked. This result is identical to the effect of dynamin inhibition in chromaffin cells using the same protocol (Elhamdani et al. 2001 ) and indicates the protocol provides a measurement of vesicle recycling and re-use in these cells. Overexpression of RCAN1 induces the same decrease in vesicle recycling. The lack of any further effect with pharmacological calcineurin inhibition indicates that RCAN1 overexpression may be inhibiting calcineurin activity to reduce recycling and re-use in subsequent stimulations. A likely mechanism underlying this is inhibition of the dephosphins, the group of structurally diverse proteins that are essential for vesicle endocytosis and which are all dephosphorylated by calcineurin. These proteins include dynamin, amphiphysin 1 and 2, synaptojanin, AP180, Epsin and Eps15 (Cousin & Robinson 2001) .
We also tested whether spike kinetics are affected by RCAN1 overexpression or calcineurin inhibition during these repeated stimulations experiments. In these experiments we hypothesised that reduced calcineurin activity, which was potentially causing changes in endocytosis, may also affect quantal release kinetics. The phosphorylation state of most exocytosis proteins, including SNARE proteins, affects their function, and subsequently the kinetics of vesicle release. For example, Munc18-1 binds to syntaxin 1 with higher affinity when dephosphorylated by calcineurin . Therefore, if calcineurin activity is decreased in RCAN1 ox cells, Munc18-1 may bind to syntaxin1 with lower affinity, resulting in unstable fusion pore formation and accelerated fusion pore kinetics. Acceleration of fusion pore kinetics as a result of decreased Munc18 phosphorylation has been previously demonstrated (Barclay et al. 2003) using Munc18 phosphomimetic mutations. The lack of effect on vesicle release kinetics by acute exposure to cyclosporine A and FK-506 indicates that short term calcineurin inhibition, even during repeated stimulation, does not alter vesicle release.
Our experiments in which we chronically inhibit calcineurin activity in WT cells are the first example illustrating that this enzyme may control vesicle release kinetics. This effect may be due to changes in phosphorylation state of Munc18 or other exocytosis proteins as discussed or alternatively, longer term exposure to cyclosporine A and FK-506 may affect release due to changes in gene transcription that take longer than the total 10-30 minute duration of the acute inhibition experiments. Calcineurin is able to affect transcription through the NFAT transcription pathway (Clipstone & Crabtree 1992) . Loss of NFAT function in pancreatic β-cells causes hypoinsulinemia due to downregulation of insulin gene transcription and insulin synthesis (Heit et al. 2006) . NFAT also regulates activity-dependent plasticity in Drosophila (Freeman et al. 2011 ) and NFAT-dependent transcription controls both morphological and electrophysiological properties of neurons (Schwartz et al. 2009 ). As amperometry measures only the release of oxidisable catecholamines, we cannot be sure if altered fusion pore kinetics underlie the reduced catecholamine release from individual vesicles or whether such changes are due to factors affecting the amount of catecholamine packaged inside each vesicle. Our electron microscopy results demonstrating a decrease in dense core volume in RCAN1 ox cells clearly point towards a defect in catecholamine loading in these cells and would argue against an effect on fusion pore kinetics. Global gene expression analysis may provide useful information regarding potential transcriptional changes occurring in RCAN1 ox chromaffin cells and whether transcriptional changes affect various secretionassociated processes.
While we observe no effect of chronic exposure to cyclosporine A and FK506 on single vesicle catecholamine release in RCAN1 ox cells, effects on PSF signal duration and area do occur. The PSF signal represents catecholamine flux through the transient, unstable fusion pore as it transitions to an open, stable full fusion pore (Zhang & Jackson 2010 , Zhou et al. 1996 . Our results present at least two intriguing possibilities. Firstly, RCAN1 may have a direct effect on the earliest stages of fusion pore formation independent of its role as a calcineurin inhibitor. There are currently no identified protein binding partners of RCAN1 which might explain such an effect. RCAN1 contains two proline-rich domains (Fuentes et al. 1995) which typically bind to SH3 regions. SH3 regions are contained in a number of proteins associated with vesicle trafficking, exocytosis and endocytosis including ITSN1 and amphiphysin 1 and 2 (Keating et al. 2006 ) but whether such interactions occur or even regulate fusion pore development is an area of future investigation. Secondly, RCAN1 overexpression in these cells may not fully inhibit calcineurin and only when calcineurin is completely inhibited pharmacologically do we see the full effect of cyclosporin A and FK506 on the PSF signal. There may therefore be differences in calcineurin sensitivity associated with the mechanisms underlying the amount released per vesicle (spike area) compared to the regulation of the PSF signal.
It must also be noted that the calcineurin inhibitors used in this study have effects other than calcineurin inhibition. In order to competitively bind to and inhibit calcineurin activity cyclosprine A forms complexes with cyclophilin D while FK506 complexes with FK506 binding protein (FKBP) (Liu et al. 1991) . Cyclophilin D can also bind the mitochondrial permeability transition pore to effect mitochondrial function (Elrod et al. 2010) while FK506 reduces the peptidyl-prolyl isomerase activity of FKBP (Brecht et al. 2003) . Thus, while calcineurin inhibition is the primary therapeutic effect of these immunosuppressants, it is possible that the changes in secretion we observe with these drugs could be independent of changes in calcineurin activity. However, given the lack of additive effect on vesicle recycling and quantal vesicle release when we overexpress an endogenous calcineurin inhibitor (RCAN1) and add known calcineurin inhibitors, our primary conclusion is that these treatments affect secretion through the same mechanism by reduced calcineurin activity.
In summary, our results demonstrate that RCAN1 regulates cell communication at several stages. Endocytosis and vesicle re-use as well as vesicle release is controlled by RCAN1 as well as by pharmacological calcineurin inhibitors, likely through the same mechanism of action of reduced calcineurin activity. What the sites of calcineurin/RCAN1 are in these instances remains to be identified. The reduction in vesicle size and catecholamine loading observed in our EM experiments seem to explain the decreased catecholamine release per vesicle in RCAN1 ox cells. Catecholamine release through the developing fusion pore is additionally affected by RCAN1. This effect of RCAN1 may be either be independent of the inhibitory action of RCAN1 on calcineurin or be explained by a differential sensitivity to calcineurin activity between early and full fusion release. Our data therefore reveals a role of RCAN1 in regulating exocytosis at several stages. Recently published data illustrates that changes in hippocampal structure and function occur in these RCAN1 ox mice brains (Martin et al. 2012) . However these changes may not be associated with alterations in calcineurin activity and involve instead changes directly associated with RCAN1 function. Therefore, while increased expression of RCAN1 may play a significant role in the cognitive and neuronal pathologies associated with Alzheimer's disease and Down syndrome, elucidating which of these are associated with the role of RCAN1 as an inhibitor of calcineurin needs to be clearly defined and may well vary for individual types of cells or neurons. This point is further highlighted by recent evidence demonstrating that the effects of RCAN1 on calcineurin are dependent on a number of factors including the degree of RCAN1 expression and the presence of other RCAN1-bidning partners that effect the relationship between RCAN1 and calcineurin (Liu et al. 2009 ). ox cells with no additional effect of acute calcineurin inhibition. Cells were stimulated 3 successive times for 1 minute with 5 minutes rest between stimulations (Elhamdani et al. 2001) . In RCAN1 ox cells we observe a gradual decline in exocytosis between the first (A), second (Β) and third (C) stimulations. (D) The average number of exocytotic events significantly decreases with this protocol (n=7 cells, *p<0.05, **p<0.01). Repeating these experiments in the acute presence of the calcineurin inhibitors, cyclosporine A and FK-506 also results in exocytotic events (E) and these reduce in frequency with a second (F) and third (G) stimulations. (H) This reduction was significant upon the second and third stimulations (H, n=4 cells, *p<0.05, **p<0.01). Figure 4 , we observe that chronic calcineurin inhibition has (A) no effect on PSF amplitude in WT or RCAN1 ox cells but decreases both (B) PSF signal duration and (C) PSF signal area in WT and RCAN1 ox cells. **P<0.01, ***P<0.001 In WT n=207 spikes in control conditions and 285 under calcineurin inhibition. In RCAN1 ox n=287 spikes in control and 166 under calcineurin inhibition.
